Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors
Further research should be directed at validating CV screening tools and measuring outcomes based on these recommendations.
Authors
- Kyle Crassini (ORCID: https://orcid.org/0000-0002-3785-2931)
- Constantine Si Lun Tam (ORCID: https://orcid.org/0000-0002-9759-5017)
- Aaron L. Sverdlov (ORCID: https://orcid.org/0000-0003-2539-8038)
- Hui‐Peng Lee
- Leanne Berkahn
- Farrukh T. Awan (ORCID: https://orcid.org/0000-0003-1813-9812)
- Paula Marlton (ORCID: https://orcid.org/0000-0003-2512-917X)
- Mark Nolan (ORCID: https://orcid.org/0000-0001-8125-929X)
- Stephen P. Mulligan (ORCID: https://orcid.org/0000-0003-1928-2098)
- Mary Ann Anderson (ORCID: https://orcid.org/0000-0002-3515-0215)
Institutions
- The Royal Melbourne Hospital (AU)
- Royal North Shore Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Auckland City Hospital (NZ)
- Princess Alexandra Hospital (AU)
- The Alfred Hospital (AU)
- Flinders Medical Centre (AU)
- Coffs Harbour City Council (AU)
- Hunter Medical Research Institute (AU)
- Northern Cancer Institute (AU)
- Calvary Mater Newcastle Hospital (AU)
- Hunter New England Local Health District (AU)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-07-26
- DOI
- https://doi.org/10.1111/imj.70159
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- AstraZeneca
- Gilead Sciences
- BeiGene
- University of Melbourne
- Novo Nordisk
- AstraZeneca Australia